News AstraZeneca's Cambridge R&D site build running years late Building not operational until 2019, says CEO
News Circassia gives up on allergy treatments after second trial ... UK biotech to focus on respiratory drugs after house dust mite therapy fails.
News Boosted by new drugs, Boehringer shrugs off patent expiry BI boosted by new diabetes and respiratory drugs.
News AZ strikes COPD deal with Circassia, suffers setback with bl... FDA rejects blood potassium drug for second time.
News Good news for GSK’s next generation asthma drug Results mean patients could switch to once-daily inhaler use
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
